News Health/Medical Labcorp Introduces New Alzheimer's Blood Biomarker Test
0
Dementia

Published :

Labcorp Introduces New Alzheimer's Blood Biomarker Test

March 20, 2024

By Copilot News

Overview

Labcorp, a global leader in innovative laboratory services, has unveiled a groundbreaking blood biomarker test to revolutionize the diagnosis and management of Alzheimer's disease. The test focuses on phosphorylated tau 217 (pTau217), a critical marker associated with Alzheimer's pathology.

Understanding Alzheimer's Disease

Alzheimer's disease, the most prevalent form of dementia, poses a significant global health challenge. Currently, approximately 6.7 million Americans live with Alzheimer's, a number projected to exceed 13.8 million by 2060.

The Role of pTau217

Labcorp's pTau217 test provides a powerful tool for clinicians and researchers. By identifying the presence or absence of pTau217, it aids in early Alzheimer's diagnosis and facilitates monitoring during treatment with novel Alzheimer's therapies.

Complementary Testing Portfolio

Labcorp's comprehensive Alzheimer's testing portfolio now includes:

  • Beta Amyloid 42/40 Ratio: An indicator of amyloid pathology, available nationwide for clinicians.
  • Neurofilament Light Chain (NfL): Measures neurodegeneration severity.
  • ATN Profile: Combines beta amyloid 42/40, NfL, and pTau181 for accessible assessment of Alzheimer's-related pathologies.

Impact and Future

Dr. Brian Caveney, Labcorp's Chief Medical and Scientific Officer, emphasized the significance of pTau217's introduction. "Expanding our suite of blood-based biomarker tests empowers clinicians and pharmaceutical partners," he stated. "We're committed to improving patient care through advanced diagnostic tools."

  • Reactions

    0
    0
    0
    0
    0
    0

    Your email address will not be published. Required fields are marked *